Read the committee members' biographies and registered interests.
Dr Jane Adam, MB BS, MRCP, FRCR
Consultant radiologist to St. George 's Hospital, London
Jane is consultant radiologist to St. George 's Hospital, London, with subspecialty interests including computerised tomography, magnetic resonance imaging and oncological imaging.
She is former chairman of both the Clinical Radiology Audit and Standards Subcommittees of the Royal College of Radiologists, former RCR Recertification Lead and previous member of RCR Education Board, Faculty Board and Council.
She was founding chair of the Audit and Standards Committee of the European Society of Radiology, chaired the Professional Organisation Committee, and is a former member of the ESR Executive Council.
Professor Abdallah Al-Mohammed
Consultant cardiologist and honorary professor of cardiology, Sheffield Teaching Hospitals NHS Foundation Trust and the University of Sheffield.
Professor Abdallah Al-Mohammad's special interests are in heart failure, infective endocarditis and cardiac imaging. He leads the heart failure service in Sheffield. He is an MRCP-PACES examiner.
Abdallah is a fellow of the Royal Colleges of Physicians of London and Edinburgh. He is specialty regional advisor for cardiology in South Yorkshire for both the Royal College of Physicians of London and the British Cardiovascular Society.
He is member of Council for the Royal College of Physicians of Edinburgh for Central England. He is a fellow of the European Society of Cardiology (ESC), a fellow of the Heart Failure Association (HFA) and a member of imaging group of the HFA-ESC. He is a member of the British Society for Heart Failure.
Abdallah had produced research in heart failure and cardiac imaging.
He has contributed to the work of NICE guidelines committees on chronic and acute heart failure, on preoperative testing and for the care of the dying adult.
Received Honorarium for:
- Attending a meeting to discuss the heart failure services with regional team of Astra Zeneca.
- Giving lectures in educational meeting sponsored by Janssen and Takeda.
- Attending an advisory board on intravenous iron with Pharmacosmos.
- Has a small private practice delivered through a limited company.
Non-financial interests professional and personal interests
- Has been a principal investigator (PI) for several clinical trials in the field of heart failure between 2001 and 2020
- He is the PI in Sheffield for the Ironman Study.
His hospital received a small grant from Astra Zeneca to purchase blood pressure machines. These were to give to patients with heart failure. This was to enable the heart failure nurses to remotely up-titrate the medication in view of the COVID-19 restrictions (£3250)
Dr Brian Shine
Consultant chemical pathologist, Oxford Radcliffe Hospitals Truste
Brian is a consultant chemical pathologist in the Oxford University Hospitals Trust and honorary senior lecturer in the Nuffield Department of Clinical Laboratory Sciences, University of Oxford. He trained in medicine in Zimbabwe, and in clinical biochemistry at St. Bartholomew's Hospital, London, and then worked at Moorfields Eye Hospital, and Stoke Mandeville Hospital.
His clinical interests are endocrinology (particularly neuroendocrine tumours and thyroid cancer), renal stone disease, metabolic bone disease, lipid disorders, and inherited metabolic disorders. His other interests include statistics, evidence based medicine, use of information technology in laboratories, postgraduate medical education, and research ethics.
Public health physician, deputy director of the Global Health and Development Group, Imperial College London
Peter is the deputy director of the Global Health and Development Group, Imperial College London, the deputy director of the international Decision Support Initiative (iDSI), an honorary public health consultant at Imperial College Healthcare NHS Trust, and a fellow of the UK's Faculty of Public Health.
His research and public health work has focused on bringing together the health and economic professions, methods, data and analysis in order to improve the use of evidence in priority setting in health, for Tower Hamlets’ Local Authority, the NHS, Public Health England, the UK’s Department for International Development and also overseas in South Africa, Rwanda, Tanzania, Sierra Leone, Zambia and Ethiopia.
Richard M. Ballerand
Richard is a Franco-British health policy advisor. With a dual finance and defence background, degrees in economics, strategy and psychology, a former military liaison officer, he later served as non-exec or trustee on think-tanks, boards and councils.
He chairs his GP’s patient participation group. He is a lay member on the NHSx National Data Collaborative for Health and Care, an NIHR Health Technology Assessment Prioritisation committee and the NHSE London Clinical Senate. He is an EMA European patient expert and active health systems networker, with roles on 4 London NHS Trusts.
Richard draws on extensive lived family experience of British, French and American healthcare systems. Having sustained a traumatic brain injury during his doctoral studies, Richard has a special interest in those with invisible disabilities and in the challenges facing both ex-military and diverse communities.
Dr Andrew Champion
Assistant director of evidence evaluation, Welsh Health Specialised Services Committee
Andrew is the assistant director of clinical effectiveness at the Welsh Heath Specialised Services Committee, the body responsible for commissioning specialised health services in Wales.
Andrew has worked in the NHS for almost 30 years, covering a wide range of research and managerial roles. After completing his PhD in radiation oncology in 1997, Andrew was appointed deputy programme coordinator for the National Specialist Advisory Group for Cancer. Here he managed implementation of improving outcomes guidance across Wales.
A strong interest in evidence based medicine led to Andrew's next appointment in 2003 as director of the NICE National Collaborating Centre for Cancer. In this role, he established a centre of excellence that developed over 25 separate NICE clinical guidelines. In 2016, Andrew left NICE to take up his current role at the Welsh Health Specialised Services Committee, where he is now embedding an evidence-based decision making approach across the organisation.
Dr Justin Daniels
Consultant paediatrician, North Middlesex University Hospital
Justin is a consultant paediatrician at North Middlesex University Hospital in North London. As well as being a general paediatrician, he has interests in paediatric HIV and paediatric dermatology.
Justin is a trustee of the Lullaby Trust, a charity that supports families who have lost a child due to sudden infant death syndrome.
Dr Steven J. Edwards
Director of health technology assessment, BMJ Technology Assessment Group (BMJ-TAG)
Steven leads one of the health technology assessment groups, funded by the National Institute for Health Research (NIHR), to conduct independent research to support health policy decision making.
Since 1999, Steven has been involved in exploring methods for evidence synthesis and health economic evaluation. His primary research interests relate to making best use of the available evidence for decision making, with an emphasis on the appropriate design and conduct of studies, aggregation of clinical data, and their use in economic modelling.
Steven is an honorary lecturer in public health at the London School of Hygiene and Tropical Medicine, a member of the Cochrane Pregnancy and Childbirth Group, and the statistics advisor for diagnostic test accuracy systematic reviews for the Cochrane Skin Group. Until April 2018, Steven was a member of the NICE Diagnostics Advisory Group.
Research fellow, Centre for Health Economics, University of York
Rita is a health economist at the Centre for Health Economics, University of York. Rita has extensive experience in economic evaluation in a wide range of areas including drugs, devices, diagnostic tests and complex interventions in health and social care. Rita’s research interests are in using economic evaluation to inform complex decision problems and non-randomised data.
Non-personal financial interest
March 2019 to present: employer receives funding from the NIHR to undertake a programme of technology assessment for NICE (assessment group, ERG and DAG work). They were awarded, led by the York Health Economics Consortium, the contract on the NICE economic and methodological unit for public health and social care. Rita is involved in some of these projects.
February 2017 to November 2018: presented to NICE DSU Masterclass on 'Selecting appropriate methods: the DSU algorithm' and 'Quality of effectiveness estimates from non-randomised studies'. Received a fee for presenting.
October 2016 to present: expert health economic reviewer for the Portuguese Committee for Evaluation of Health Care Technologies (Comissão de Avaliação de Tecnologias de Saúde (CATS)), for INFARMED, which is the Portuguese Health Technology Assessment Agency. In this capacity she conducts a critical appraisal of the economic evidence on drugs seeking reimbursement from the Portuguese National Health Service. The economic evidence is submitted by the manufacturer to INFARMED. She doesn't make decisions about whether the drug is cost-effective nor if reimbursement is warranted. She receives a fee for conducting each critical appraisal.
March 2018 to present: involved in the update of the methods guide for economic evaluation for the INFARMED. No payment received for this work.
April 2019 to present: teaches a ABPI/NICE/DSU Masterclass each year titled 'Using non randomised data to estimate treatment effects in NICE submissions' for which she receives a fee.
Dr Rishiraj Hazarika
Head of market access and tender excellence, Alcon
Rishiraj originally trained as a surgeon, practising within the NHS, and advanced to senior clinical leadership positions. He has also worked in central government at Monitor, which was the economic regulator for the NHS.
Prior to Alcon, Rishiraj led the global management consultancy services for a non-for-profit organisation founded by Harvard Business School and the Boston Consulting Group. This focused on standardising the measurement of health outcomes and expanding the adoption of value-based-healthcare.
Dr Michael V Holmes, MD PhD MRCP MFPM
Associate professor and pharmaceutical physician, University of Oxford
Michael trained in medicine, epidemiology and genetics and is undergoing specialist training in pharmaceutical physician. He is associate professor at the Nuffield Department of Population Health at the University of Oxford, where he leads genetic investigations to elucidate the causes of cardiovascular disease. Michael is associate director of the NHS Genomic Medicine Service Alliance, which is tasked with embedding genomics into healthcare in the NHS.
Non-financial professional and personal interests
Unpaid consultancy for Boehringer Ingelheim, advising on pharmacogenetic investigations of medicinal products that have data from several clinical trials.
Committee member of British Atherosclerosis Society.
Professor of psychiatry and medicine, King’s College London
Khalida is a clinical academic psychiatrist at King’s Health Partners. She has a special interest in the epidemiology of psychiatric disorders in diabetes, such as depression, eating disorders and psychotic disorders. She also has a special interest in developing and evaluating interventions to improve diabetes self-management.
Chief pharmacist, London Ambulance Service NHS Trust
Having completed her pharmacy undergraduate degree at Kings College London, Sumithra has gained extensive experience in clinical pharmacy across hospital and commissioning. She also has a Masters in Business Administration from Imperial College Business School.
Sumithra has particular interest in medication safety, evidence-based medicines and guidelines.
May 2019: Consultancy fee for advisory board 3rd April 2019 regarding a product manufactured by Veriton pharma via Integ Ltd.
G.J. Melendez-Torres DPhil RN
Director, Peninsula Technology Assessment Group, University of Exeter
G.J. is a professor of clinical and social epidemiology and director of the Peninsula Technology Assessment Group at the University of Exeter, one of 9 research units in the UK providing expert advice on the clinical and cost effectiveness of new drugs to the National Institute for Health and Care Excellence. He holds first degrees in nursing and health economics as well as a doctorate in social epidemiology.
His primary interests in health technology assessment relate to applications of network meta-analysis, as well as the use of HTA in public health and complex interventions.
Non-financial professional and personal interest
March 2019 to present: leads the Peninsula Technology Appraisal Group, commissioned to provide HTA for NICE appraisal committees.
Sarah Parry RN, BSc (Hons), MSc
Clinical nurse specialist in paediatric acute and palliative pain management, Department of Paediatric Anaesthesia, University Hospital Bristol NHS Foundation Trust
Sarah is an experienced nurse and lead clinical nurse specialist for paediatric pain medicine at Bristol Royal Hospital for Children. She has clinical experience in a large variety of paediatric specialities spanning over two decades and has held a number of senior posts within the NHS. Areas of experience include research methodology, systematic reviews and patient safety with a keen focus on medication.
Sarah's qualifications include a masters in pain and advance nursing practice. She also participated in the development of the RCN paediatric pain assessment guidelines. Additional roles outside of the NHS include:
- core member of the RCN children and younger person’s pain group
- honouree lecturer at both Cardiff University and University of the West of England
- specialist adviser for the Care Quality Commission (CQC).
Sarah has two sons that keep her work-life balance in order. She enjoys most sports, particularly skiing, and keeps fit doing yoga and swimming. But most importantly, she is enthusiastic supporter of welsh rugby!
Research fellow (health economics), ScHARR, University of Sheffield
Becky is a health economist at the School of Health and Related Research, University of Sheffield. Becky is a member of the Decision Support Unit and her research interests are methods for cost-effectiveness analysis. Becky is undertaking a National Institute for Health Research fellowship researching the inclusion of carer health-related quality of life in economic evaluation.
Becky has previously worked for NICE in developing guidelines, and in consultancy with pharmaceutical companies.
Non-financial professional and personal interests
January 2018 to present: involved in ongoing research project funded by NIHR to determine cost-effectiveness of ranibizumab, aflibercept and bevacizumab for macular oedema due to central retinal vein occlusion.
January 2018 to present: authored documents submitted as evidence to technology appraisal committees relating to effectiveness and cost-effectiveness of teduglutide for short bowel syndrome.
February to November 2018: authored documents submitted as evidence to technology appraisal committees relating to effectiveness and cost-effectiveness of dinutuximab beta for neuroblastoma.
May 2017 to present: employer receives payment from pharmaceutical companies for consultancy work but does not work on or receive funding from these projects.
UK market access director, AbbVie Ltd
Dominic is UK market access director for AbbVie Ltd, a biopharmaceutical company. He leads a team focused on enabling patient access to innovative medicines. Dominic has worked in the pharmaceutical industry for over 15 years, gaining experience across a range of therapeutic areas. He started his career in commercial roles before moving into the field of patient access and health technology assessment (HTA).
Dominic holds an MSc in Economic Evaluation for HTA from the University of York, a Postgraduate Diploma in Marketing from the Chartered Institute of Marketing, and a BSc (Hons) in Environmental Sciences from the University of East Anglia. He is also guest lecturer in the Faculty of Health and Life Sciences at Coventry University.
Ms Pamela Rees
After obtaining an undergraduate degree and a post graduate certificate in education, Pamela undertook postgraduate studies in urban and regional planning at the Architectural Association, London. She is currently studying for her Masters in Public Health at Nottingham University.
Pamela has taught in secondary, further and adult education for over ten years before going into youth work and then to work with Nottingham City Council in community development and regeneration. She has worked with the probation service in both paid and voluntary roles to address health inequalities. She is currently a member of the NIHR Research and Design service East Midlands Regional Advisory Board and Public Involvement committee.
In 2006-7, Pamela was a community member of the NICE Public Health Programme Development Group for the Smoking Cessation Services guidance (NICE PH10). She has worked with ‘disadvantaged' communities for over thirty years and for the past decade the main focus of her work has been on improving patient and public understanding of and involvement in health; improving information and access to appropriate health care services and enabling individuals to take greater responsibility for their own health. Her commitment to social inclusion, equality and supporting public involvement in the forces that shape their lives owes much to this experience and to her personal experience as a carer.
June 2017 - present: a public reviewer for National Institute for Health Research and has been appointed to NIHR East Midlands Panel for Patient Benefit. Receives an honorarium for reviewing research funding applications. None of this work has involved drugs or other technologies that have been appraised by TAC A or any other TAC that she's been a member of.
Dr Mohit Sharma
Consultant in healthcare, Public Health England
Mr Stephen Sharp
Senior statistician, University of Cambridge MRC Epidemiology Unit
Mr Min Ven Teo
Min is a clinical pharmacist in a general practice and clinical director for the local primary care network. He was trained at the Welsh School of Pharmacy and subsequently completed an International Masters in Health Technology Assessment and Management under the Ulysses Programme. He spent 2017 to 2018 as a NICE Scholar and is currently a NICE medicine and prescribing associate.
Min has an interest in evidence based medicine and decision making.
Non-financial and personal interest
April 2018 to present: NICE medicines and prescribing associate.
Professor Alice Turner
Consultant in respiratory medicine, Heartlands hospital
Alice graduated from the University of Leicester. She has done postgraduate training via the Universities of Dundee and Birmingham, completing a PhD focussed on COPD and alpha 1 antitrypsin deficiency (AATD).
She has been a consultant in respiratory medicine at Heartlands hospital since 2011, and is a reader in respiratory medicine at University of Birmingham. In addition she has been a member of the BTS specialist advisory group on COPD and the European Respiratory Society task force on AATD. She has published widely in COPD and AATD, and has ongoing research projects funded by the Alpha 1 Foundation, NIHR, ATS Foundation and others.
2016 to present: consultancy fee received from CSL Behring for advisory board in area of alpha 1 antitrypsin deficiency (AATD); since this condition is rare it is unlikely to affect her work on committee A, as any drugs from this company would likely go to the HST committee instead. Work started 2016 and is likely to continue in financial year 2019-20.
2018: honoraria received for educational talk/event from Chiesi about COPD in 2018, not continuing in 2019-20.
2016 to present: honoraria due to be received for steering committee of an observational study run by Boehringer-Ingelheim in AATD and COPD, started 2016 and study recently extended to 2021.
2017 to present: employer manages research grant from AstraZeneca for a study in COPD due to end 2020.
2018 to present: employer manages research grant from Chiesi for a study in COPD due to end 2021.
April 2019 to present: employer manages research grant from CSL Behring for a study in AATD. Currently going through contracting, due to end in 2020.
Dr Roger Whittaker
Clinical senior lecturer, Institute of Neuroscience, Newcastle University
Roger is professor of clinical neurophysiology in the Translational and Clinical Research Institute, Newcastle University, and Honorary Consultant in the Department of Clinical Neurophysiology in the Royal Victoria Infirmary, Newcastle upon Tyne. His clinical and research focus is on developing and testing novel diagnostic techniques for patients with neurological diseases.